A Clinical Trial of TQB3454 Tablets in Healthy Adult Subjects

Biliary Carcinoma Clinical Trial

Official title:

A Randomized, Open, Parallel, Single Center Phase I Clinical Trial to Evaluate the Effect of Food on the Pharmacokinetics of TQB3454 Tablets in Healthy Adult Subjects.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06139367
• Other study ID #: TQB3454-I-03
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: November 2023
• Est. completion date: December 2023

Study information

• Verified date: November 2023
• Source: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Contact: Yu Cao, Master of Medicine
• Phone: 18661809090
• Email: caoyu1767[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, open, parallel, single center phase I clinical trial to evaluate the impact of food on the pharmacokinetics of TQB3454 tablets in healthy adult subjects. The aim is to evaluate the impact of food on the pharmacokinetics as well as the safety after single dose of TQB3454 tablets taken orally by Chinese healthy adult subjects, with pharmacokinetic indicators as the primary endpoint.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 40
• Est. completion date: December 2023
• Est. primary completion date: December 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Sign an informed consent form before the experiment and fully understand the content, process, and potential adverse reactions of the study;
• Able to complete the study according to the requirements of the protocol;
• Subjects aged 18-65 (inclusive);
• Body mass index (BMI) = 18 and = 28 kg/m^2, and male's weight = 50 kg and female's weight = 45 kg;
• Health status: No mental abnormalities, no history of severe neurological, respiratory, digestive, urinary, endocrine, and metabolic abnormalities;
• The subjects have no pregnancy plan, voluntarily take effective contraceptive measures, and no plans to donate sperm or eggs, from the date of signing the inform consent (14 days before signing the inform consent for female subjects) to at least 6 months after the last administration.

Exclusion Criteria:

• Subjects with allergic constitution or a history of allergies to two or more foods or drugs;
• Subjects who have experienced arterial/venous thrombosis events within 6 months, such as cerebrovascular accidents (including temporary ischemic attacks), deep vein thrombosis, and pulmonary embolism;
• Suffering from = Level 2 myocardial ischemia or infarction, arrhythmia (including QTc = 450 ms for male, QTc = 470 ms for female), and = Level 2 congestive heart failure (New York Heart Association (NYHA) classification);
• Those with multiple factors that affect oral medication (such as inability to swallow, gastrointestinal diseases);
• Have taken any prescription, over-the-counter, vitamin product, or herbal medicine within one month before the first administration;
• Take CYP3A4 inhibitors or inducers within one month before the first administration or before the study medication;
• Those who have taken a special diet (including grapefruit, etc.) or engaged in vigorous exercise within 14 days before the first administration or have other factors that affect drug absorption, distribution, metabolism, excretion, etc.;
• Abnormal and clinically significant physical examination, vital signs, electrocardiogram, and laboratory tests during the screening period;
• Donated blood or experienced significant blood loss (>450 mL) within 3 months prior to taking the study drug;
• Participated in any clinical trial and took any investigational drug within 3 months prior to taking the study drug;
• Smoke at least 5 cigarettes per day within 3 months prior to the study;
• Positive alcohol breath test or history of alcoholism within 2 weeks prior to screening (drinking 14 units of alcohol per week: 1 unit=360 mL of beer or 45 mL of 40% alcohol or 150 mL of wine);
• Drug screening positive or those who have used drugs in the past 3 months prior to the study;
• Inability to tolerate venous puncture for blood collection or poor vascular condition;
• The subject is unable to complete the experiment due to personal reasons;
• Other conditions that it is considered not suitable for enrollment assessed by the investigators.

Related Conditions & MeSH terms

• Biliary Carcinoma

Intervention

Drug:
• TQB3454 tablets
TQB3454 is a Isocitrate dehydrogenase 1 (IDH1) mutation inhibitor.

Locations

Country	Name	City	State
China	The Affiliated Hospital of Qingdao University	Qingdao	Shandong

Sponsors (1)

Lead Sponsor	Collaborator
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Peak concentration (Cmax)	Maximum plasma drug concentration	pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 264, 330 hours after dose.
Primary	Area under the time-concentration curve from 0 to t hours (AUC0-t)	Area under the plasma concentration-time curve from the time of first dose to the time of the last measurable concentration.	pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 264, 330 hours after dose.
Primary	Area under the time-concentration curve from 0 to infinity (AUC0-8)	Area under the plasma concentration-time curve from the time of first dose extrapolated to infinity	pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 264, 330 hours after dose.
Primary	Time to peak (Tmax)	Time to reach maximum plasma concentration after drug administration	pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 264, 330 hours after dose.
Primary	Elimination half-life (t1/2)	The time it takes for the blood concentration of a drug to decrease from its highest value to half in the body.	pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 264, 330 hours after dose.
Primary	Apparent volume of distribution (Vd/F)	The ratio of the amount of drug in the body to the concentration in the blood.	pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 264, 330 hours after dose.
Primary	Apparent clearance (CL/F)	Apparent total clearance of the drug from plasma after oral administration.	pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 264, 330 hours after dose.
Primary	Elimination rate constant (?z)	Terminal disposition rate constant/terminal rate constant	pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 264, 330 hours after dose.
Primary	Lag time (tlag)	The time required from the start of administration to the appearance of the drug in the blood.	pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 264, 330 hours after dose.
Primary	Percentage of residual area (AUC% Extrap)	Residual area as a percentage of the entire area under curve.	pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 264, 330 hours after dose.
Secondary	Adverse event rate	The incidence of adverse events (AEs), abnormal laboratory test values, and severe adverse events (SAEs).	Before the first administration to 360 hours after the last administration.
Secondary	Adverse event severity	The severity of adverse events (AEs), abnormal laboratory test values, and severe adverse events (SAEs).	Before the first administration to 360 hours after the last administration.